Anti-CD19 antibody [6D5] (ab25232)
Key features and details
- Rat monoclonal [6D5] to CD19
- Suitable for: Flow Cyt
- Reacts with: Mouse
- Isotype: IgG2a
Related conjugates and formulations
Overview
-
Product name
Anti-CD19 antibody [6D5]
See all CD19 primary antibodies -
Description
Rat monoclonal [6D5] to CD19 -
Host species
Rat -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
Tissue, cells or virus corresponding to Mouse CD19. Mouse CD19-expressing K562 human erythroleukemia cells
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 8.20
Constituent: 100% Borate buffered saline -
Concentration information loading...
-
Purity
Affinity purified -
Clonality
Monoclonal -
Clone number
6D5 -
Isotype
IgG2a -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab25232 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt |
Use at an assay dependent concentration.
ab18450 - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
Notes |
---|
Flow Cyt
Use at an assay dependent concentration. ab18450 - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
Target
-
Function
Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. -
Involvement in disease
Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low. -
Sequence similarities
Contains 2 Ig-like C2-type (immunoglobulin-like) domains. -
Post-translational
modificationsPhosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 12478 Mouse
- SwissProt: P25918 Mouse
- Unigene: 4360 Mouse
-
Alternative names
- Antibody deficiency due to defect in CD19 antibody
- Antibody deficiency due to defect in CD19, included antibody
- AW495831 antibody
see all
Images
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (19)
ab25232 has been referenced in 19 publications.
- Ukita M et al. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight 7:N/A (2022). PubMed: 35552285
- Giannoccaro MP et al. Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodies. Brain 142:2000-2012 (2019). PubMed: 31079141
- Yang X et al. Depletion of microglia augments the dopaminergic neurotoxicity of MPTP. FASEB J 32:3336-3345 (2018). PubMed: 29401614
- Zhang J et al. In situ administration of cytokine combinations induces tumor regression in mice. EBioMedicine 37:38-46 (2018). PubMed: 30297145
- Yuan FY et al. Tanshinone IIA improves diabetes mellitus via the NF-?B-induced AMPK signal pathway. Exp Ther Med 16:4225-4231 (2018). PubMed: 30344697